secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001193125-22-200433
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo to acquire Zymergen for ~$300M all-stock; Zymergen holders get 0.9179 DNA shares
--------------------------------------------------------------------------------

- Deal valued at ~$300M market cap; fixed exchange ratio of 0.9179 Ginkgo shares per Zymergen share.
- Zymergen stockholders will own 5.25% of pro forma combined company after transaction close.
- Voting agreements from holders of ~40% of Zymergen shares to vote in favor of the merger.
- Integration expected to accelerate Ginkgo's platform; Zymergen to evaluate strategic alternatives for Advanced Materials and Drug Discovery.
- Transaction subject to regulatory approvals, Zymergen stockholder vote, and other conditions; expected close by Jan 24, 2023 with extension options.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522200433/0001193125-22-200433-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000119312522200433/d368627d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-200433

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer